PD13-04 TRENDS IN DIAGNOSIS AND TREATMENT OF T1A, T1B PROSTATE CANCER IN THE UNITED STATES, 2010-2017

Abstract

You have accessJournal of UrologyCME1 May 2022PD13-04 TRENDS IN DIAGNOSIS AND TREATMENT OF T1A, T1B PROSTATE CANCER IN THE UNITED STATES, 2010-2017 Eyal Kord, Hannah Koenig, On Ho, John Paul Flores, and Christopher Porter Eyal KordEyal Kord More articles by this author , Hannah KoenigHannah Koenig More articles by this author , On HoOn Ho More articles by this author , John Paul FloresJohn Paul Flores More articles by this author , and Christopher PorterChristopher Porter More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002545.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Currently, there is no consensus regarding optimal treatment for incidental prostate cancer (PCa) finding after surgical treatment for benign prostate obstruction. In addition, changing recommendations regarding PCa screening in the US during the last decade, have led to changes in incidence patterns of PCa. We aimed to assess recent trends in diagnosis and treatment of T1a, T1b PCa in the US. METHODS: Using the National Cancer Database, we identified patients diagnosed with T1a, T1b, and T1c PCa between 2010-2017. We described rates of diagnosis, change in clinically significant disease, and patients risk stratification over the time-period studied. Use of treatment modalities was compared between the risk stratified groups. We used the two-way ANOVA and Tukey post Hoc Tests to examine significant changes in incidence and treatment. RESULTS: We identified 24,679 patients diagnosed with T1a (15,186) or T1b (9,493) PCa between 2010-2017. Newly diagnosed T1a/b cases represented an average of 3.54% of all PCa cases without a significant change in incidence over the years. The chance of T1a/b being clinically significant (CS) increased steadily and significantly over time representing 38.7% in 2010 and 44.1% in 2017 (p <0.001). Low, intermediate, and high-risk disease comprised 72.3%,20.9%, and 6.8% of T1a, and 27.3%,33.5%, and 39.2% of T1b diagnosis, respectively. In comparison to T1c, patients diagnosed with T1a/b disease were older (62.2 Vs 70.3 for Low, 64.4 Vs 72.3 for intermediate, and 67.1 Vs 76.4 for high risk, p <0.001) and had a higher comorbidity score across all risk groups. (0.18 Vs 0.42 for Low, 0.23 Vs 0.46 for intermediate, and 0.27 Vs 0.45 for high risk, p <0.001) Across all risk groups, patients diagnosed with T1a/b disease were significantly less likely to be treated definitively with surgery or radiation, and more likely to be treated with active surveillance/watchful waiting or androgen deprivation therapy in comparison to T1c patients (Table 1). CONCLUSIONS: Although the incidence of T1a/b PCa remained stable, the chance of CS disease diagnosis increased between 2010-2017. In comparison to T1c, men diagnosed incidentally with T1a/b disease are less likely to receive definitive treatment by surgery or radiation. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e252 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Eyal Kord More articles by this author Hannah Koenig More articles by this author On Ho More articles by this author John Paul Flores More articles by this author Christopher Porter More articles by this author Expand All Advertisement PDF DownloadLoading ...